[go: up one dir, main page]

WO2017064092A1 - Additifs alimentaires pour animaux aquatiques comprenant des huiles essentielles et un lysozyme - Google Patents

Additifs alimentaires pour animaux aquatiques comprenant des huiles essentielles et un lysozyme Download PDF

Info

Publication number
WO2017064092A1
WO2017064092A1 PCT/EP2016/074407 EP2016074407W WO2017064092A1 WO 2017064092 A1 WO2017064092 A1 WO 2017064092A1 EP 2016074407 W EP2016074407 W EP 2016074407W WO 2017064092 A1 WO2017064092 A1 WO 2017064092A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acids
lysozyme
alpha
feed
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2016/074407
Other languages
English (en)
Inventor
Viviane VERLHAC
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Priority to CA3001389A priority Critical patent/CA3001389A1/fr
Priority to EP16784817.5A priority patent/EP3361882A1/fr
Priority to CN201680058693.7A priority patent/CN108289478A/zh
Publication of WO2017064092A1 publication Critical patent/WO2017064092A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/105—Aliphatic or alicyclic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/189—Enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K40/00—Shaping or working-up of animal feeding-stuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract

Definitions

  • the present invention relates to the use of natural essential oil actives in combination with at least one polypeptide having lysozyme activity in the manufacture of feed for aquatic animals including fish and shrimp, especially for cold water fish as for example salmon, bream, bass and for warm water fish as for example carp, tilapia, catfish.
  • SEQ ID NO: 1 is the mature amino acid sequence of a wild type GH25 lysozyme from Acremonium alcalophilum as described in WO 2013/076253.
  • SEQ ID NO: 2 is the gene sequence of the GH24 lysozyme as isolated from Tri- chophaea saccata.
  • SEQ ID NO: 3 is the amino acid sequence as deduced from SEQ ID NO: 2.
  • SEQ ID NO: 4 is the mature amino acid sequence of a wild type GH24 lysozyme from Trichophaea saccata.
  • SEQ ID NO: 5 is the mature amino acid sequence of a wild type GH22 lysozyme from Gallus gallus (hen egg white lysozyme).
  • SEQ ID NO: 6 is primer F-80470.
  • SEQ ID NO: 7 is primer R-80470.
  • SEQ ID NO: 8 is primer 8643.
  • SEQ ID NO: 9 is primer 8654.
  • the present invention relates to the use of natural essential oil actives selected from the group consisting of alpha-pinene, alpha-terpineol, cinnamaldehyde, di- hydroeugenol, eugenol, meta-cresol and terpinolene in the manufacture of feed for aquatic animals including fish and shrimp, especially for cold water fish as for example salmon, bream, bass and for warm water fish as for example carp, tilapia, catfish.
  • natural essential oil actives selected from the group consisting of alpha-pinene, alpha-terpineol, cinnamaldehyde, di- hydroeugenol, eugenol, meta-cresol and terpinolene in the manufacture of feed for aquatic animals including fish and shrimp, especially for cold water fish as for example salmon, bream, bass and for warm water fish as for example carp, tilapia, catfish.
  • this invention relates to the use of at least one, preferably at least two essential oil actives as defined above in combination with a polypeptide having lysozyme activity for the improvement of the feed conversion ratio and/or daily weight gain in fish, for reducing mortality by regulating the micro flora of the gut and/or by protecting the animal against infections caused by pathogenic microor- ganisms.
  • Lysozyme is an O-glycosyl hydrolase produced as a defensive mechanism against bacteria by many organisms.
  • the enzyme causes the hydrolysis of bacterial cell walls by cleaving the glycosidic bonds of peptidoglycan; an important structural molecule in bacteria. After having their cell walls weakened by lysozyme action, bacterial cells lyse resulting from osmotic pressure.
  • Lysozyme occurs in many organisms such as viruses, plants, insects, birds, reptiles and mammals. In mammals, Lysozyme has been isolated from nasal secretions, saliva, tears, intestines, urine and milk. The enzyme cleaves the glycosidic bond between carbon number 1 of /V-acetylmuramic acid and carbon number 4 of /V-acetyl-D-glucosamine. In vivo, these two carbohydrates are polymerized to form the cell wall polysaccharide.
  • Lysozyme has been classified into five different glycoside hydrolase (GH) families (CAZy, www.cazy.org): hen egg-white lysozyme (GH22), goose egg-white lysozyme (GH23), bacteriophage T4 lysozyme (GH24), Sphingomonas flagellar pro- tein (GH73) and Chalaropsis lysozymes (GH25). Lysozymes from the families GH23 and GH24 are primarily known from bacteriophages and have only recently been identified in fungi. The lysozyme family GH25 has been found to be structurally unrelated to the other lysozyme families.
  • GH glycoside hydrolase
  • Hen egg white lysozyme is the primary product available on the commercial mar- ket, but does not cleave A/,6-0-diacetylmuramic acid in e.g. Staphylococcus aureus cell walls and is thus unable to lyse this important human pathogen among others (Masschalck B, Deckers D, Michiels CW (2002), "Lytic and nonlytic mechanism of inactivation of gram-positive bacteria by lysozyme under atmospheric and high hydrostatic pressure", J Food Prot. 65(12):1916-23).
  • the present invention relates to a novel fish feed composition
  • a novel fish feed composition comprising as active ingredients at least one, preferably at least two or three active compound(s) selected from the group consisting of alpha-pinene, alpha-terpineol, cinnamaldehyde, dihydroeugenol, eugenol, meta-cresol and terpinolene in combi- nation with at least one microbial polypeptide having lysozyme activity.
  • Turnover rate is determined by how fast the fish grow to a harvestable size. As an example, it takes from 12 to 18 months to raise Atlantic salmon from smolt (the physiological stage when the Atlantic salmon can first be transferred from fresh water to sea water) to harvestable size. A fast turnover has several positive results. First, it helps cash flow. Second, it improves risk management. Especially, a high mortality rate is a substantial risk for fish farmers.
  • antibiotics and vaccines are widely used in aquaculture, antibiotics are not so much used - at least in cold water aquaculture - due to the fact that disease spread very quickly, diseased fish do not eat much and also due to the negative impact on the environment of the wasted medicated feed.
  • Vaccines are widely used when available but they are not developed for all diseases.
  • patent WO201 1/006993 describes the use of essential oils in fish feed.
  • WO201 1/006993 is however silent with regard to the protection against infections caused by gram+ microorganisms.
  • the application of essential oils has in the disclosed case above only limited efficiency. It therefore remains a need in aquaculture to prevent the development of diseases, thereby reducing mortality by any prophylactic means including antimicrobial activity against gram+ microorganisms.
  • the inventors of the present application surprisingly found that the combination of substances as defined above have a great potential for use in fish feed, e.g. for improving the feed conversion ratio (FCR) and/or weight gain and/or for the modulation of the gut flora. Further, the inventors surprisingly found that the novel fish feed compositions have also antimicrobial activity against gram+ microorganisms resulting in a reduced mortality.
  • the unique selection of active compounds of the present invention allows for the first time controlling a number of fish diseases caused by a number of different pathogens.
  • the invention relates to methods for using at least one, preferably at least two active compounds selected from the group consisting of alpha-pinene, alpha-terpineol, cinnamaldehyde, dihydroeuge- nol, eugenol, meta-cresol and terpinolene in combination with a microbial lyso- zyme in fish feed for improving the Feed Conversion Ratio (FCR) and/or weight gain and/or for reducing mortality by modulation of the gut microflora and/or by preventing diseases caused by pathogenic microorganisms, preferably caused by gram+ microorgansims.
  • FCR Feed Conversion Ratio
  • selected compounds of the invention eg.: cinnamaldehyde and alpha-pinene in combination with a bacterial lysozyme
  • the combination according to the present invention also exhibits excellent effects against Streptococcus iniae, a disease found especially in warm water fish.
  • alpha-pinene and/or alpha-terpineol and/or cinnamaldehyde and/or dihydroeugenol and/or eugenol and/or meta-cresol and/or terpinolene is/are used in combination with at least one microbial polypeptide having lysozyme activity to improve animal feed digestibility and/or maintain animal health by supporting immune system function.
  • the invention relates to methods for using at least three active compounds selected from the group consisting of alpha-pinene, alpha- terpineol, cinnamaldehyde, dihydroeugenol, eugenol, meta-cresol and terpinolene in combination with at least one microbial polypeptide having lysozyme activity in fish feed for improving the Feed Conversion Ratio (FCR) and/or weight gain and/or for reducing mortality by modulation of the gut microflora and/or by preventing diseases caused by pathogenic microorganisms.
  • FCR Feed Conversion Ratio
  • alpha-pinene and cinnamaldehyde are used in combination with a bacterial lysozyme to improve animal feed digestibility and/or maintain animal health by supporting immune system function.
  • feed or feed composition means any compound, preparation, mixture, or composition suitable for, or intended for intake by an animal.
  • the FCR may be determined on the basis of a fish growth trial comprising a first treatment in which a mixture of at least two compounds according to the invention is added to the animal feed in a suitable concentration per kg feed, and a second treatment (control) with no addition of the compound(s) to the animal feed.
  • an improved FCR is lower than the control FCR.
  • the FCR is improved (i.e., reduced) as compared to the control by at least 1 .0 %, preferably at least 1 .5 %, 1 .6 %, 1 .7 %, 1 .8 %, 1 .9 %, 2.0 %, 2.1 %, 2.2 %, 2.3 %, 2.4 %, or at least 2.5 %.
  • the term "gut” as used herein designates the gastrointestinal or digestive tract (also referred to as the alimentary canal) and it refers to the system of organs within multi-cellular animals which takes in food, digests it to extract energy and nutrients, and expels the remaining waste.
  • gut “microflora” refers to the natural microbial cultures residing in the gut and maintaining health by aiding in proper digestion.
  • module as used herein in connection with the gut microflora generally means to change, manipulate, alter, or adjust the function or status thereof in a healthy and normally functioning animal, i.e. a non-therapeutic use.
  • supporting immune system function refers to the immune stimulation effect obtained by the compounds.
  • the term "mortality" as used herein refers to the ratio of life animals at the end of the growth phase versus the number of animals originally included into the pond. It may be determined on the basis of a fish challenge trial comprising two groups of fish challenged by a particular fish pathogen with the aim to provoke a mortality of 40 to 80 % of the animals in the untreated group. However, in the challenge group fed with a suitable concentration per Kg of feed of a mixture of at least two compounds according to the invention, the mortality is reduced compared to the untreated group by at least 5 %, preferably at least, 10 %, 15 %, 20 %, 25 %, 30 %, 35 %, 40 %, 45 %, or at least 50 %.
  • Animal feed refers to any compound, preparation, or mixture suitable for, or intended for intake by an animal.
  • Animal feed for a monogas- trie animal typically comprises concentrates as well as vitamins, minerals, enzymes, direct fed microbial, amino acids and/or other feed ingredients (such as in a premix) whereas animal feed for ruminants generally comprises forage (including roughage and silage) and may further comprise concentrates as well as vitamins, minerals, enzymes direct fed microbial, amino acid and/or other feed ingre- washers (such as in a premix).
  • Antimicrobial activity is defined herein as an activity that kills or inhibits the growth of microorganisms, such as, algae, archea, bacteria, fungi and/or protozoans.
  • the antimicrobial activity can for example be bactericidal meaning the killing of bacteria or bacteriostatic meaning the preven- tion of bacterial growth.
  • the antimicrobial activity can include catalyzing the hydrolysis of 1 ,4-beta-linkages between /V-acetylmuramic acid and /V-acetyl-D- glucosamine residues in a peptidoglycan and between /V-acetyl-D-glucosamine residues in chitodextrins.
  • Antimicrobial activity can also include the lysozyme binding to the surface of the microorganism and inhibiting its growth.
  • the antimi- crobial effect can also include the use of the lysozymes of the present invention for activation of bacterial autolysins, as an immunostimulator, by inhibiting or reducing bacterial toxins and by an opsonin effect.
  • antimicrobial activity is determined according to the antimicrobial assay described in Example 6 ("Determination of an- timicrobial activity"). Antimicrobial activity is determined by the diameter of the clearing zone and is evaluated as significant if the clearing zone is more than 2 mm using 50% Mueller-Hinton broth, pH 6.
  • Concentrates means feed with high protein and energy concentrations, such as fish meal, molasses, oligosaccharides, sorghum, seeds and grains (either whole or prepared by crushing, milling, etc. from e.g. corn, oats, rye, barley, wheat), oilseed press cake (e.g. from cottonseed, safflower, sunflower, soybean (such as soybean meal), rapeseed/canola, peanut or groundnut), palm kernel cake, yeast derived material and distillers grains (such as wet distillers grains (WDS) and dried distillers grains with solubles (DDGS)).
  • high protein and energy concentrations such as fish meal, molasses, oligosaccharides, sorghum, seeds and grains (either whole or prepared by crushing, milling, etc. from e.g. corn, oats, rye, barley, wheat), oilseed press cake (e.g. from cottonseed, safflower, sunflower, soybean (such as soybean meal
  • European Production Efficacy Factor The European Production Efficacy Factor is a way of comparing the performance of animals. This single-figure facilitates comparison of performance within and among farms and can be used to assess environmental, climatic and managemental variables.
  • the EPEF is calcu- lated as [(liveability (%) x Liveweight (kg)) / (Age at depletion (days) x FCR)] x 100, wherein livability is the percentage of animals alive at slaughter, Liveweight is the average weight of the animals at slaughter, age of depletion is the age of the animals at slaughter and FCR is the feed conversion ratio at slaughter.
  • FCR Feed Conversion Ratio
  • fragment means a polypeptide or a catalytic domain having one or more ⁇ e.g., several) amino acids absent from the amino and/or carboxyl terminus of a mature polypeptide or domain; wherein the fragment has lysozyme or phytase activity.
  • a fragment comprises at least 170 amino acids, such as at least 175 amino acids, at least 177 amino acids, at least 180 amino ac- ids, at least 185 amino acids, at least 190 amino acids, at least 195 amino acids or at least 200 amino acids of SEQ ID NO: 1 and has lysozyme activity.
  • a fragment comprises at least 210 amino acids, such as at least 215 amino acids, at least 220 amino acids, at least 225 amino acids, at least 230 amino acids, at least 235 amino acids or at least 240 amino acids of SEQ ID NO: 4 and has lysozyme activity.
  • Isolated means a substance in a form or environment that does not occur in nature.
  • isolated substances include (1 ) any non-naturally occurring substance, (2) any substance including, but not limited to, any enzyme, variant, nucleic acid, protein, peptide or cofactor, that is at least partially removed from one or more or all of the naturally occurring constituents with which it is associated in nature; (3) any substance modified by the hand of man relative to that substance found in nature; or (4) any substance modified by increasing the amount of the substance relative to other components with which it is naturally associated ⁇ e.g., multiple copies of a gene encoding the sub- stance; use of a stronger promoter than the promoter naturally associated with the gene encoding the substance).
  • An isolated substance may be present in a fermentation broth sample.
  • Lysozyme activity means the hydrolysis of the 1 ,4- beta-linkages between /V-acetylmuramic acid and /V-acetyl-D-glucosamine resi- dues in a peptidoglycan or between /V-acetyl-D-glucosamine residues in chitodex- trins, resulting in bacteriolysis. Lysozyme belongs to the enzyme class EC
  • Lysozyme activity is typically measured by turbidimetric determination. The method is based on the changes in turbidity of a suspension of Micrococcus luteus ATCC 4698 induced by the lytic action of lysozyme. In appropriate experi- mental conditions these changes are proportional to the amount of lysozyme in the medium (c.f. INS 1 105 of the Combined Compendium of Food Additive Specifications of the Food and Agriculture Organisation of the UN (www.fao.org)).
  • lysozyme activity is determined according to the turbidity assay described in example 5 ("Determination of Lysozyme Activity").
  • the polypeptides of the present invention have at least 20%, e.g., at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 100% of the lysozyme activity of SEQ ID NO: 1 .
  • the polypeptides of the present invention have at least 20%, e.g., at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 100% of the lysozyme activity of SEQ ID NO: 4.
  • Mature polypeptide means a polypeptide in its final form following translation and any post-translational modifications, such as N-terminal processing, C-terminal truncation, glycosylation, phosphorylation, etc.
  • Microbial lysozyme means a polypeptide having lysozyme activity which is obtained or obtainable from a microbial source.
  • microbial sources are fungi.
  • the microbial lysozyme is obtained or obtainable from the phylum Ascomycota, such as the sub-phylum
  • Sequence identity The relatedness between two amino acid sequences or be- tween two nucleotide sequences is described by the parameter "sequence identity”.
  • the sequence identity between two amino acid sequences is determined using the Needleman-Wunsch algorithm (Needle- man and Wunsch, 1970, J. Mol. Biol. 48: 443-453) as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et ai, 2000, Trends Genet. 16: 276-277), preferably version 5.0.0 or later.
  • the parameters used are gap open penalty of 10, gap extension penalty of 0.5, and the EBLOSUM62 (EMBOSS version of BLOSUM62) substitution matrix.
  • substantially pure polypeptide means a preparation that contains at most 10%, at most 8%, at most 6%, at most 5%, at most 4%, at most 3%, at most 2%, at most 1 %, and at most 0.5% by weight of other polypeptide material with which it is natively or recombinantly associated.
  • the polypeptide is at least 92% pure, e.g., at least 94% pure, at least 95% pure, at least 96% pure, at least 97% pure, at least 98% pure, at least 99%, at least 99.5% pure, and 100% pure by weight of the total polypeptide material present in the preparation.
  • polypeptides of the present invention are preferably in a substantially pure form. This can be accomplished, for example, by preparing the polypeptide by well known recombinant methods or by classical purification methods.
  • variant means a polypeptide having lysozyme or phytase activity comprising an alteration, i.e., a substitution, insertion, and/or deletion, of one or more (several) amino acid residues at one or more ⁇ e.g., several) positions.
  • a lysozyme variant according to the invention may comprise from 1 to 5; from 1 to 10; from 1 to 15; from 1 to 20; from 1 to 25; from 1 to 30; from 1 to 35; from 1 to 40; from 1 to 45; or from 1 -50, i.e.
  • a lysozyme variant according to the invention may comprise from 1 to 5; from 1 to 10; from 1 to 15; from 1 to 20; from 1 to 25; from 1 to 30; from 1 to 35; from 1 to 40; from 1 to 45; or from 1 -50, i.e.
  • compositions according to the invention were shown to exhibit inhibitory effect against Lactococ- cus garvieae a disease found especially in cold water fish and against Streptococcus iniae, a disease found especially in warm water fish.
  • the use of at least one microbial polypeptide having lysozyme activi- ty in combination as defined above further improves existing inhibitory effects of natural essential oil actives.
  • Alpha-pinene, cinnamaldehyde, dihydroeugenol, eugenol, limonene, and meta- cresol were shown to exhibit inhibitory effect against Aeromonas salmonicida which is the pathogen causing a disease known as furunculosis.
  • Alpha-pinene, alpha-terpineol, cinnamaldehyde, dihydroeugenol, eugenol, meta- cresol and terpinolene were shown to exhibit inhibitory effect against Edwardsellia tarda causing systemic infection in fish.
  • Alpha-pinene, alpha-terpineol, cinnamaldehyde, dihydroeugenol, eugenol, and terpinolene were shown to exhibit inhibitory effect against Lactococcus garvieae which is the etiological agent of Latococcosis, an emergent disease which affects many fish species and causes important economic losses both in marine and freshwater aquaculture when water temperature increases over 16 °C in summer months.
  • Cinnamaldehyde, dihydroeugenol, eugenol, and meta-cresol exhibit excellent inhibitory effects on the growth of Yersinia ruckeri, a pathogenic microorganism which causes Enteric Redmouth (ERM), a disease found especially in salmonids. Cinnamaldehyde and meta-cresol were shown to exhibit inhibitory effect against:
  • pathogen is very resistant to conventional simple antimicrobials like chlorine.
  • Piscirickettsia salmonis the causative agent of piscirickettsiosis or salmonid rickettsial septicaemia (SRS), - Vibrio viscosus recently renamed Moritella viscosa etiologically responsible for the disease referred to as "winter ulcer",
  • Vibrio harveyi responsible for luminous vibriosis, a disease that affects commercially-farmed prawns will also be inhibited by the compound mixture described in the present invention.
  • the present invention provides a fish feed composition
  • a fish feed composition comprising at least one microbial peptide having lysozyme activity in combination with at least two active compounds selected from the group consisting of alpha-pinene (CAS 99-86-5), alpha-terpineol (CAS 98-55-5), cinnamaldehyde (CAS 14371 -10-9 / 104-55-2), dihydroeugenol (CAS 2785-87-7), eugenol (CAS 97-53-0), meta- cresol (CAS 108-39-4) and terpinolene (CAS 554-61 -0).
  • the compounds according to the invention are commercially available or can easily be prepared by a skilled person using processes and methods well-known in the prior art.
  • the compounds of the invention can be used alone or in mixtures thereof, in the form of natural available extracts or extract-mixtures or in the form of a natural substance.
  • extract as used herein includes compositions obtained by solvent ex- traction (which are also known as “extracted oils”), steam distillation (which are also known as “essential oils”) or other methods known to the skilled person.
  • Suitable extraction solvents include alcohols such as ethanol.
  • the active essential oil compound(s) or natural substance or extract further ingredients may be added in minor amounts.
  • examples of such ingredients are: capsaicin, tannin, piperin, trimethylamine, 3,4,xylenol, furfuryl alcohol and mixtures thereof.
  • cinnamaldehyde and/or meta-cresol are used as a major component of the mixture.
  • the mixture contains 10-90 % by weight of meta-cresol and/or cinnamaldehyde, 1 -50 % by weight of alpha-pinene, 1 -50 % by weight of dihydro- eugenol, wherein the amounts being calculated on the total amount of said com- ponents.
  • the total amount of these active ingredients may vary within wide limits but is finally used in the fish feed from 10 to 5000 ppm, preferably between 100 and 1000 ppm, calculated on the dry weight of the fish feed.
  • the most preferred mixture of at least two essential oil compounds as specified above comprises, cinnamaldehyde and alpha-pinene as a major component of the mixture.
  • the mixture contains 30-70 % by weight of alpha-pinene, 30-70 % by weight cinnamaldehyde, 1 -20 % by weight of metacresol, 1 -20 % by weight of dihydro-eugenol, wherein the amounts being calculated on the total amount of said components.
  • the total amount of these active ingredients may vary within wide limits but is finally used in the fish feed from 10 to 5000 ppm, preferably be- tween 100 and 1000 ppm, calculated on the dry weight of the fish feed.
  • All essential oil compounds defined herein above may be used in combination with an emulsifying surfactant.
  • the emulsifying agent can be selected advantageously from those of a rather hydro- philic nature, for example among polyglycerol esters of fatty acids such as esteri- fied ricinoleic acid or propylene glycol esters of fatty acids, saccharo-esters or saccharo-glycerides, polyethylene glycol, lecithins etc.
  • a mixture of essential oils may contain 20 % by weight of cinnamaldehyde, 20 % by weight of meta-cresol, 20 % by weight of dihydro-eugenol, 20 % by weight of alpha-pinene, 3 % by weight of trimethylamine, 1 .8 % by weight of piperin and 4 % by weight of furfuryl alcohol.
  • a mixture of essential oil active compounds contains 40 to 60 wt.-% alpha-pinene, 40 to 60 wt.-% cinnamaldehyde, and may further contain 1 to 5 wt.-% trimethylamine, 1 to 5 % piperin, and 3 to 8 wt.-% furfuryl alcohol.
  • the invention also relates to a method of improving the European Production Efficiency Factor (EPEF) comprising administering an animal feed or animal feed additive comprising at least two essential oil compounds and one or more microbial lysozymes to the animal.
  • EPEF European Production Efficiency Factor
  • the improvement is compared to an animal feed or animal feed additive wherein the microbial lysozyme is not present (herein referred to as the control).
  • the EPEF is improved by at least 1 %, such as by at least 1 .5%, at least 2.0%, at least 2.5%, at least 3%, at least 3.5%, at least 4% or at least 5% compared to the control. In another embodiment, the EPEF is improved by between 1 % and 15%, such as between 1 % and 12%, between 1 % and 10%, 1 .5% and 8%, 2.0% and 7% compared to the control, or any combination of these intervals.
  • the microbial lysozyme is dosed at a level of 8 to 250 ppm enzyme protein per kg animal feed, such as 9 to 200 ppm, 10 to 150 ppm, 1 1 to 125 ppm, 12 to 100 ppm, 13 to 75 ppm, 15 to 50 ppm, 17.5 to 40 ppm, 25 to 75 ppm or 30 to 60 ppm enzyme protein per kg animal feed, or any combination of these intervals.
  • the microbial lysozyme is of fungal origin.
  • the microbial lysozyme is obtained or obtainable from the phylum Ascomycota, such as the sub-phylum Pezizomycotina.
  • the microbial lysozyme comprises one or more domains se- lected from the list consisting of GH24 and GH25.
  • the invention relates to a method of improving the European Production Efficiency Factor (EPEF) and/or feed conversion ratio (FCR) comprising administering an animal feed or animal feed additive comprising one or more microbial lysozymes to the fish, wherein: (a) the microbial lysozyme is a microbial lysozyme comprising one or more domains selected from the list consisting of GH24 and GH25, is dosed at a level of 10 to 150 ppm enzyme protein per kg animal feed;
  • EPEF European Production Efficiency Factor
  • FCR feed conversion ratio
  • the aquatic animal is a selected from shrimp, for cold water fish as for example salmon, bream, bass and for warm water fish as for example carp, tilapia, catfish and;
  • EPEF European Production Efficiency Factor
  • FCR feed conversion ratio
  • the microbial lysozyme is of fungal origin. In an embodiment, the microbial lysozyme is obtained or obtainable from the phylum Ascomycota, such as the sub-phylum Pezizomycotina.
  • the microbial lysozyme has at least 50%, e.g., at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1 .
  • the microbial lysozyme comprises or consists of the amino acid sequence of SEQ ID NO: 1 or an allelic variant thereof; or is a fragment thereof having lysozyme activity, wherein the fragment comprises at least 170 amino acids, such as at least 175 amino acids, at least 177 amino acids, at least 180 amino acids, at least 185 amino acids, at least 190 amino acids, at least 195 amino acids or at least 200 amino acids.
  • the microbial lysozyme comprises or consists of the amino acid sequence of SEQ ID NO: 1 or an allelic variant thereof and a N-terminal and/or C-terminal His-tag and/or HQ-tag.
  • the polypeptide comprises or consists of amino acids 1 to 208 of SEQ ID NO: 1 .
  • the microbial lysozyme is a variant of SEQ ID NO: 1 wherein the variant has lysozyme activity and comprises one or more substitutions, and/or one or more deletions, and/or one or more insertions or any combination thereof in 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49 or 50 positions.
  • the number of positions comprising one or more amino acid substitutions, and/or one or more amino acid deletions, and/or one or more amino acid insertions or any combination thereof in SEQ ID NO: 1 is between 1 and 45, such as 1 -40, 1 -35, 1 -30, 1 -25, 1 -20, 1 -15, 1 -10 or 1 -5 positions. In an embodiment, the number of positions comprising one or more amino acid substitutions, and/or one or more amino acid deletions, and/or one or more amino acid insertions or any combination thereof in SEQ ID NO: 1 is not more than 10, e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10.
  • the number of substitutions, deletions, and/or insertions in SEQ ID NO: 1 is not more than 10, e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10. In a further embodiment, the number of substitutions, preferably conservative substitutions, in SEQ ID NO: 1 is not more than 10, e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10. In a further embodiment, the number of conservative substitutions in SEQ ID NO: 1 is not more than 10, e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10.
  • amino acid changes may be of a minor nature, that is conservative amino acid substitutions or insertions that do not significantly affect the folding and/or activ- ity of the protein; small deletions, typically of 1 -30 amino acids; small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue; a small linker peptide of up to 20-25 residues; or a small extension that facilitates purification by changing net charge or another function, such as a poly-histidine tract, an antigenic epitope or a binding domain.
  • conservative substitutions are within the groups of basic amino acids (arginine, lysine and histidine), acidic amino acids (glutamic acid and aspartic acid), polar amino acids (glutamine and asparagine), hydrophobic amino acids (leucine, isoleucine and valine), aromatic amino acids (phenylalanine, tryptophan and tyrosine), and small amino acids (glycine, alanine, serine, threonine and methio- nine).
  • Amino acid substitutions that do not generally alter specific activity are known in the art and are described, for example, by H. Neurath and R.L. Hill, 1979, In, The Proteins, Academic Press, New York.
  • Essential amino acids in a polypeptide can be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, 1989, Science 244: 1081 -1085). In the latter technique, single alanine mutations are introduced at every residue in the molecule, and the resultant mutant molecules are tested for lysozyme activity to identify amino acid residues that are critical to the activity of the molecule. See also, Hilton et ai, 1996, J. Biol. Chem. 271 : 4699-4708.
  • the active site of the enzyme or other biological interaction can also be determined by physical analysis of structure, as determined by such techniques as nuclear magnetic resonance, crystallography, electron diffraction, or photoaffinity labeling, in conjunction with mutation of putative contact site amino acids. See, for example, de Vos et ai, 1992, Science 255: 306-312; Smith et ai, 1992, J. Moi Biol. 224: 899-904;
  • the crystal structure of the Acremonium alcalophilum CBS1 14.92 lysozyme was solved at a resolution of 1 .3 A as disclosed in WO 2013/076253. These atomic coordinates can be used to generate a three dimensional model depicting the structure of the Acremonium alcalophilum CBS1 14.92 lysozyme or homologous structures (such as the variants of the present invention). Using the x/ray structure, amino acid residues D95 and E97 (using SEQ ID NO: 1 for numbering) were identified as catalytic residues.
  • the microbial lysozyme has at least 50%, e.g., at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 4.
  • the microbial lysozyme comprises or consists of the amino acid sequence of SEQ ID NO: 4 or an allelic variant thereof; or is a fragment thereof having lysozyme activity, wherein the fragment comprises at least 210 amino acids, such as at least 215 amino acids, at least 220 amino acids, at least 225 amino acids, at least 230 amino acids, at least 235 amino acids or at least 240 amino acids.
  • the microbial lysozyme comprises or consists of the amino acid sequence of SEQ ID NO: 4 or an allelic variant thereof and a N-terminal and/or C-terminal His-tag and/or HQ-tag.
  • the polypeptide comprises or consists of amino acids 1 to 245 of SEQ ID NO: 4.
  • the microbial lysozyme is a variant of SEQ ID NO: 4 wherein the variant has lysozyme activity and comprises one or more substitutions, and/or one or more deletions, and/or one or more insertions or any combination thereof in 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49 or 50 positions.
  • the number of positions comprising one or more amino acid substitutions, and/or one or more amino acid deletions, and/or one or more amino acid insertions or any combination thereof in SEQ ID NO: 4 is between 1 and 45, such as 1 -40, 1 -35, 1 -30, 1 -25, 1 -20, 1 -15, 1 -10 or 1 -5 positions. In an embodiment, the number of positions comprising one or more amino acid substitutions, and/or one or more amino acid deletions, and/or one or more amino acid insertions or any combination thereof in SEQ ID NO: 4 is not more than 10, e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10.
  • the number of substitutions, deletions, and/or insertions in SEQ ID NO: 4 is not more than 10, e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10. In a further embodiment, the number of substitutions, preferably conservative substitutions, in SEQ ID NO: 4 is not more than 10, e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10. In a further embodiment, the number of conservative substitutions in SEQ ID NO: 4 is not more than 10, e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10.
  • the enzyme of the invention may be formulated as a liquid or a solid.
  • the formulating agent may comprise a polyol (such as e.g. glycerol, ethylene glycol or propylene glycol), a salt (such as e.g. sodium chloride, sodium benzoate, potassium sorbate) or a sugar or sugar derivative (such as e.g. dextrin, glucose, sucrose, and sorbitol).
  • the composition is a liquid composition
  • the enzyme(s) of the invention and one or more formulating agents selected from the list consisting of glycerol, ethylene glycol, 1 ,2-propylene glycol, 1 ,3-propylene glycol, sodium chloride, sodium benzoate, potassium sorbate, dextrin, glucose, sucrose, and sorbitol.
  • the liquid formulation may be sprayed onto the feed after it has been pelleted or may be added to drink- ing water given to the animals.
  • the formulation may be for example as a granule, spray dried powder or agglomerate.
  • the formulating agent may comprise a salt (organic or inorganic zinc, sodium, potassium or calcium salts such as e.g. such as calcium acetate, calcium benzoate, calcium carbonate, calcium chloride, calcium citrate, calcium sorbate, calcium sulfate, potassium acetate, potassium benzoate, potassium carbonate, potassium chloride, potassium citrate, potassium sorbate, potassium sulfate, sodium acetate, sodium benzoate, sodium carbonate, sodium chloride, sodium citrate, sodium sulfate, zinc acetate, zinc benzoate, zinc carbonate, zinc chloride, zinc citrate, zinc sorbate, zinc sulfate), starch or a sugar or sugar derivative (such as e.g. sucrose, dextrin, glucose, lactose, sorbitol).
  • a sugar or sugar derivative such as e.g. sucrose, dextrin, glucose, lactose, sorbitol
  • the solid composition is in granulated form.
  • the granule may have a matrix structure where the components are mixed homogeneously.
  • the granule typically comprises a core particle and one or more coatings, which typically are salt and/or wax coatings.
  • the core particle can either be a homogeneous blend of the enzyme(s) of the invention optionally combined with one or more additional enzymes and optionally together with one or more salts or an inert particle with the enzyme(s) of the invention optionally combined with one or more additional enzymes applied onto it.
  • the material of the core particles are selected from the group consisting of inorganic salts (such as calcium acetate, calcium benzoate, calcium carbonate, calcium chloride, calcium citrate, calcium sorbate, calcium sulfate, potassium acetate, potassium benzoate, potassium carbonate, potassium chloride, potassium citrate, potassium sorbate, potassium sulfate, sodium acetate, sodium benzoate, sodium carbonate, sodium chloride, sodium citrate, sodium sulfate, zinc acetate, zinc benzoate, zinc carbonate, zinc chloride, zinc citrate, zinc sorbate, zinc sulfate), starch or a sugar or sugar derivative (such as e.g.
  • inorganic salts such as calcium acetate, calcium benzoate, calcium carbonate, calcium chloride, calcium citrate, calcium sorbate, calcium sulfate, potassium acetate, potassium benzoate, potassium carbonate, potassium chloride, potassium citrate, potassium sorbate, potassium sulfate, sodium acetate, sodium be
  • sucrose, dextrin, glucose, lactose, sorbitol sugar or sugar derivative (such as e.g. sucrose, dextrin, glucose, lactose, sorbitol), small organic molecules, starch, flour, cellulose and minerals.
  • the salt coating is typically at least 1 ⁇ thick and can either be one particular salt or a mixture of salts, such as Na2SO 4 , K 2 SO 4 , MgSO 4 and/or sodium citrate. Other examples are those described in e.g. WO 2008/017659, WO 2006/034710, WO 1997/05245, WO 1998/54980, WO 1998/55599, WO 2000/70034 or polymer coating such as described in WO 2001/00042.
  • the composition is a solid composition comprising the en- zyme(s) of the invention and one or more formulating agents selected from the list consisting of sodium chloride, sodium benzoate, potassium sorbate, sodium sulfate, potassium sulfate, magnesium sulfate, sodium thiosulfate, calcium car- bonate, sodium citrate, dextrin, glucose, sucrose, sorbitol, lactose, starch and cellulose.
  • the formulating agent is selected from one or more of the following compounds: sodium sulfate, dextrin, cellulose, sodium thiosulfate and calcium carbonate.
  • the solid composition is in granulated form.
  • the solid composition is in granulated form and comprises a core particle, an enzyme layer comprising the enzyme(s) of the invention and a salt coating.
  • the formulating agent is selected from one or more of the following compounds: glycerol, ethylene glycol, 1 , 2-propylene glycol or 1 , 3- propylene glycol, sodium chloride, sodium benzoate, potassium sorbate, sodium sulfate, potassium sulfate, magnesium sulfate, sodium thiosulfate, calcium carbonate, sodium citrate, dextrin, glucose, sucrose, sorbitol, lactose, starch and cellulose.
  • the formulating agent is selected from one or more of the following compounds: 1 , 2-propylene glycol, 1 , 3-propylene glycol, sodium sulfate, dextrin, cellulose, sodium thiosulfate and calcium carbonate.
  • the incorporation of the fish feed composition containing the active compound(s) into the fish feed may be performed as described in example 1 .
  • the mixture of active compounds is then prepared directly as an oil which is then mixed with the oil sprayed onto the feed pellets as described in example 1 .
  • the incorporation of the fish feed composition containing the active compound(s) into the fish feed may alternatively be carried out by preparing a premix of the active ingredients and other suitable additives.
  • a premix may comprise 2-10 % by weight of the active mixture or natural substance or extract, 0-40 % by weight of other conventional additives, such as flavorings, and 50-98 % by weight of any conventional absorbing support.
  • the support may contain, for example, 40-50 % by weight of wood fibers, 8-10 % by weight of stearin, 4-5 % by weight of curcuma powder, 4-5 % by weight of rosemary powder, 22-28 % by weight of limestone, 1 -3 % by weight of a gum, such as gum Arabic, 5-50 % by weight of sugar and/or starch and 5-15 % by weight of water.
  • a gum such as gum Arabic
  • 5-50 % by weight of sugar and/or starch and 5-15 % by weight of water.
  • This premix is then mixed with vitamins, as for example vitamin C, mineral salts and other feed additive ingredients, as for example yeast extracts containing nucleotides, glucan and other gut microflora modulators and then finally added to the feed in such quantities that the feed will contain 10-5000 ppm, preferably 100- 1000 ppm or 100-500 ppm of the active ingredients according to the invention.
  • vitamins as for example vitamin C
  • mineral salts as for example yeast extracts containing nucleotides, glucan and other gut microflora modulators
  • composition of the present invention will be preferably used together with yeast extract containing nucleotides, and glucan.
  • feed-additive ingredients are coloring agents, e.g. carotenoids such as beta-carotene, astaxanthin, and lutein; aroma compounds; stabilisers; antimicrobial peptides; polyunsaturated fatty acids; and/or at least one enzyme selected from amongst phytase (EC 3.1 .3.8 or 3.1 .3.26); xylanase (EC 3.2.1 .8); galactanase (EC 3.2.1 .89); alpha-galactosidase (EC 3.2.1 .22); protease (EC 3.4.), phospholipase A1 (EC 3.1 .1 .32); phospholipase A2 (EC 3.1 .1 .4);
  • lysophospholipase (EC 3.1 .1 .5); phospholipase C (EC 3.1 .4.3); phospholipase D (EC 3.1 .4.4); amylase such as, for example, alpha-amylase (EC 3.2.1 .1 ); and/or beta-glucanase (EC 3.2.1 .4 or EC 3.2.1 .6).
  • polyunsaturated fatty acids examples include C18, C20 and C22 polyunsaturated fatty acids, such as arachidonic acid, docosohexaenoic acid, eicosapentaenoic acid and gamma-linoleic acid.
  • the fish feed as described herein has a proximate composition of 20-60 wt.-% protein, and 1 -45 wt.-% moisture and lipid.
  • the fish feed comprises one or more of sources of:
  • - protein, carbohydrate and lipid for example, fish meal, fish oil, blood meal, feather meal, poultry meal, chicken meal and/or other types of meal produced from other slaughterhouse waste
  • - vegetable meal e.g. soya meal, lupin meal, pea meal, bean meal, rape meal and/or sunflower meal
  • soya meal e.g. soya meal, lupin meal, pea meal, bean meal, rape meal and/or sunflower meal
  • rapeseed oil e.g. rapeseed oil, soya oil
  • - gluten e.g. wheat gluten or corn gluten
  • fish feed as used herein includes a fish feed composition according to the invention and components as described above.
  • fish feed includes fish meal as a component.
  • fish feed is in the form of flakes or pellets, for example extruded pellets.
  • the invention in a third aspect, relates to a feed composition for aquatic animals and to the use of this composition for feeding fish.
  • the feed is particularly suitable for feeding salmonids, including Atlantic salmon (Salmo salar), other salmon species and trout, and non-salmonids such as cod, sea bass, sea bream and eel.
  • salmonids including Atlantic salmon (Salmo salar), other salmon species and trout, and non-salmonids such as cod, sea bass, sea bream and eel.
  • it can be fed to all types of fish, for example turbot, halibut, yellow tail and tuna.
  • the main raw materials are ground and mixed. Microingredients are then added to the mixer and the homogenous mix is conditioned by adding water and steam to the mass in a preconditioner. This starts a cooking process in the starch fraction (the binding component).
  • the mass is fed into a pellet mill. The mass is forced through the mill's die and the strings are broken into pellets on the outside of the die. The moisture content is low and drying of the feed is not necessary.
  • Additional oil including a fish feed composition according to the present invention is then sprayed onto the surface of pellets, but as the pellets are rather compact, the total lipid content rarely exceeds 24 %.
  • the added oil may be fish oil or vegetable oils, for example rape seed oil or soy oil, or a mixture of vegetable oils or a mixture of fish oil and vegetable oils.
  • the pellets are cooled in a cooler and bagged.
  • the final pressed fish feed contains 10 to 5000 ppm of the composition as described in the invention.
  • Example 2 Method for Preparation of Extruded Fish Feed
  • the main raw materials are ground and mixed.
  • Micro ingredients incl. a fish feed composition according to the invention are added to the mixer.
  • the homogenous mix is conditioned by adding water and steam to the mass in a preconditioner. Additional oil may also be added to the mass at this stage. This starts a cooking process in the starch fraction (the binding component).
  • the mass is fed into an extruder.
  • the extruder may be of the single screw or the twin-screw type. Due to the rotational movement of the mass in the extruder, the mass is further mixed. Additional oil, water and steam may be added to the mass in the extruder. At the end of the extruder, the mass has a temperature above 100 °C and a pressure above ambient pressure.
  • the mass is forced through the openings in the extruder's die plate. Due to the relief in temperature and pressure, some of the moisture will evaporate immediately (flash off) and the extruded mass becomes porous.
  • the strings are cut into pellets by a rotating knife. The water content is rather high (18-28 %) and the pellets are therefore immediately dried to
  • Oil may be added to the feed by spraying oil onto the surface of the feed, or by dipping the feed in oil. It is advantageous to add the oil to the feed in a closed vessel where the air pressure is below ambient (vacuum coating) so that the porous feed pellets absorb more oil. Feed containing more than 40 % lipid may be produced this way. After the coater, the feed is cooled and bagged. Oil may be added at several places in the process as explained above, and may be fish oil or vegetable oils, by example rape seed oil or soy oil, or a mixture of vegetable oils or a mixture of fish oil and vegetable oils.
  • the dominant protein source in dry feed for fish has been fish meal of different qualities.
  • Other animal protein sources are also used for dry fish feed.
  • chicken meal typically cheaper than fish meal and fish oil.
  • vegetable protein such as wheat gluten, maize (corn) gluten, soya protein, lupin meal, pea meal, bean meal, rape meal, sunflower meal and rice flour.
  • Example 3 Evaluation of the effect of the active compounds according to the invention on survival of Lactococcus garvieae and Streptococcus iniae.
  • the antimicrobial activity of the composition of the invention towards of Lactococcus garvieae and Streptococcus iniae were determined in vitro. Feeding regime:
  • Bacteria All tested pathogenic strains belong to the strain collection of the Centre for fish and wildlife health, Institute of Animal Pathology, University of Bern (Switzerland).
  • Determination of suitable bacteria dilution From a 24 hour old subculture of bacteria on blood sheep agar (Biomerieux, Geneva) a small amount was trans- ferred to sterile NaCI until a McFarland value of 0.5 was obtained. From this solution 3, 1 .5 and 0.75 % dilutions in TSB were made on 96 well plates with round bottoms. Each well received a total volume of 100 ⁇ . After 24 hours at 22 °C the growth of bacteria was assessed. The dilution resulting in a well demarcated spot covering half of the round bottom well was selected for the experiments. Determination of solvent effect: To solve test substances in TSB agar, alcohol (ETOH) was used. To determine a possible effect of alcohol, the calculated final concentrations of alcohol in the test wells (0.1 , 0.05 and 0.025 %) were tested with different concentrations of bacteria, and did not show any effect on bacterial growth.
  • Concentration of test substances The in vitro dose range was estimated considering a probable dietary concentration of at least 1000 ppm and a daily feeding rate of 2 %. The potential concentration in the gut was established at maximum 0.1 ⁇ /100 ⁇ . A serial 2 dilution was then tested leading to final concentrations of the substance of 0.85 ⁇ g ml; 0.42 ⁇ g ml and 0.21 ⁇ g ml when adjusted to average essential oil density.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Husbandry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Insects & Arthropods (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Fodder In General (AREA)
  • Feed For Specific Animals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne l'utilisation de substances naturelles actives, choisies dans le groupe constitué de l'alpha-pinène, de l'alpha-terpinéol, du cinnamaldéhyde, du dihydro-eugénol, de l'eugénol, du métacrésol et du terpinolène, en combinaison avec un polypeptide ayant une activité de lysozyme, dans la fabrication d'une composition alimentaire destinée aux animaux aquatiques, en particulier aux poissons d'eau froide comme, par exemple, le saumon, la brème, la perche, mais aussi aux poissons d'eau chaude comme la carpe, le tilapia et le poisson-chat. La présente invention concerne, plus précisément, l'utilisation d'une substance telle que définie ci-dessus, pour améliorer le coefficient de transformation des aliments et/ou le gain pondéral quotidien chez le poisson, pour réguler la microflore intestinale et pour protéger l'animal contre les infections provoquées par des microorganismes pathogènes, en particulier des microorganismes gram+.
PCT/EP2016/074407 2015-10-13 2016-10-12 Additifs alimentaires pour animaux aquatiques comprenant des huiles essentielles et un lysozyme Ceased WO2017064092A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA3001389A CA3001389A1 (fr) 2015-10-13 2016-10-12 Additifs alimentaires pour animaux aquatiques comprenant des huiles essentielles et un lysozyme
EP16784817.5A EP3361882A1 (fr) 2015-10-13 2016-10-12 Additifs alimentaires pour animaux aquatiques comprenant des huiles essentielles et un lysozyme
CN201680058693.7A CN108289478A (zh) 2015-10-13 2016-10-12 包含精油和溶菌酶的用于水生动物的饲料添加剂

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15189495.3 2015-10-13
EP15189495 2015-10-13

Publications (1)

Publication Number Publication Date
WO2017064092A1 true WO2017064092A1 (fr) 2017-04-20

Family

ID=54293139

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/074407 Ceased WO2017064092A1 (fr) 2015-10-13 2016-10-12 Additifs alimentaires pour animaux aquatiques comprenant des huiles essentielles et un lysozyme

Country Status (5)

Country Link
EP (1) EP3361882A1 (fr)
CN (1) CN108289478A (fr)
CA (1) CA3001389A1 (fr)
CL (1) CL2018000925A1 (fr)
WO (1) WO2017064092A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017000922A1 (fr) 2015-07-02 2017-01-05 Novozymes A/S Compositions d'aliments pour animaux et utilisations de celles-ci
WO2019121937A1 (fr) * 2017-12-20 2019-06-27 Dsm Ip Assets B.V. Compositions d'aliments pour animaux comprenant de la muramidase et leurs utilisations
WO2019121930A1 (fr) * 2017-12-20 2019-06-27 Dsm Ip Assets B.V. Compositions d'aliments pour animaux et leurs utilisations
WO2019207053A1 (fr) * 2018-04-25 2019-10-31 Novozymes A/S Compositions d'aliments pour animaux et leurs utilisations
CN110621779A (zh) * 2017-05-12 2019-12-27 诺维信公司 具有溶菌酶活性的多肽、编码其的多核苷酸以及其用途和组合物
WO2020058225A1 (fr) * 2018-09-17 2020-03-26 Dsm Ip Assets B.V. Compositions d'aliments pour animaux et leurs utilisations
WO2020058223A1 (fr) * 2018-09-17 2020-03-26 Dsm Ip Assets B.V. Composition d'aliment pour animaux et son utilisation

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109105665B (zh) * 2018-09-05 2022-05-17 山东大学 一种筛选大菱鲆饲料保护剂的方法
CN109170369A (zh) * 2018-10-10 2019-01-11 徐州市宏翔蛋白饲料有限公司 一种含鸭肉骨粉饲料的配方
BE1027041B1 (nl) * 2019-02-08 2020-09-08 Nutrition Sciences Nv Samenstelling voor gebruik bij de behandeling van piscirickettsiose

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011006993A1 (fr) * 2009-07-17 2011-01-20 Dsm Ip Assets B.V. Utilisation de substances naturelles en tant qu'additifs alimentaires pour animaux aquatiques
US20130101634A1 (en) * 2011-10-12 2013-04-25 Deerland Enzymes, Inc. Compositions and methods for reducing microbial overgrowth in the small intestines
WO2013076253A1 (fr) * 2011-11-25 2013-05-30 Novozymes A/S Polypeptides ayant une activité de lysozyme et polynucléotides codant pour ces polypeptides

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504490B1 (en) * 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
JP2002316909A (ja) * 2000-12-22 2002-10-31 Erubu:Kk 機能性材料
DE102004019751A1 (de) * 2004-04-23 2005-11-17 Henkel Kgaa Neue Alkalische Proteasen und Wasch- und Reinigungsmittel, enthaltend diese neuen Alkalischen Proteasen
US7354888B2 (en) * 2004-11-10 2008-04-08 Danisco A/S Antibacterial composition and methods thereof comprising a ternary builder mixture
US8088976B2 (en) * 2005-02-24 2012-01-03 Monsanto Technology Llc Methods for genetic control of plant pest infestation and compositions thereof
ES2487642T3 (es) * 2007-06-29 2014-08-22 Dsm Ip Assets B.V. Composición de aditivos para piensos que comprende ácido benzoico y una mezcla de compuestos de aceites esenciales adsorbidos
HU229104B1 (hu) * 2007-11-22 2013-07-29 Pharmateka Bt EDTA és sói felhasználása Brachyspira hyodysenteriae által okozott sertésdizentéria megelõzésére és kezelésére és antibiotikumok ilyen betegségekben kifejtett hatásának fokozására szolgáló készítmények elõállítására
CN101773513A (zh) * 2009-01-14 2010-07-14 邢建慧 天然抗菌组分阴道pH值一致型水溶性人体润滑剂
CN103571613A (zh) * 2012-08-06 2014-02-12 湖北大自然农业实业有限公司 一种黄荆挥发油的制备方法
CN104673558A (zh) * 2013-11-30 2015-06-03 楚乐然 除螨香皂
CN104256194B (zh) * 2014-10-14 2016-07-06 湖南百宜饲料科技有限公司 一种功能型保命猪奶粉教槽料
CN104286420A (zh) * 2014-10-27 2015-01-21 天津市世昌科技发展有限公司 提高种用毛皮动物产仔产奶性能的饲料添加剂及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011006993A1 (fr) * 2009-07-17 2011-01-20 Dsm Ip Assets B.V. Utilisation de substances naturelles en tant qu'additifs alimentaires pour animaux aquatiques
US20130101634A1 (en) * 2011-10-12 2013-04-25 Deerland Enzymes, Inc. Compositions and methods for reducing microbial overgrowth in the small intestines
WO2013076253A1 (fr) * 2011-11-25 2013-05-30 Novozymes A/S Polypeptides ayant une activité de lysozyme et polynucléotides codant pour ces polypeptides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOHN THOMAS ET AL: "Pathogenecity of Pseudomonas aeruginosa in Oreochromis mossambicus and treatment using lime oil nanoemulsion", COLLOIDS AND SURFACES. B, BIOINTERFACES, vol. 116, 24 January 2014 (2014-01-24), NL, pages 372 - 377, XP055328526, ISSN: 0927-7765, DOI: 10.1016/j.colsurfb.2014.01.019 *
S. SIAVASH SAEI-DEHKORDI ET AL: "Chemical composition, antioxidative capacity and interactive antimicrobial potency of Satureja khuzestanica Jamzad essential oil and antimicrobial agents against selected food-related microorganisms", INTERNATIONAL JOURNAL OF FOOD SCIENCE AND TECHNOLOGY., vol. 47, no. 8, 8 May 2012 (2012-05-08), GB, pages 1579 - 1585, XP055328335, ISSN: 0950-5423, DOI: 10.1111/j.1365-2621.2012.03006.x *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017000922A1 (fr) 2015-07-02 2017-01-05 Novozymes A/S Compositions d'aliments pour animaux et utilisations de celles-ci
EP3317293A4 (fr) * 2015-07-02 2019-03-20 Novozymes A/S Compositions d'aliments pour animaux et utilisations de celles-ci
US12324447B2 (en) 2015-07-02 2025-06-10 Novozymes A/S Animal feed compositions and uses thereof
US10945449B2 (en) 2015-07-02 2021-03-16 Novozymes A/S Animal feed compositions and uses thereof
US12428632B2 (en) 2017-05-12 2025-09-30 Novozymes A/S Polypeptides having lyzozyme activity, polunucleotides encoding same and uses and compositions thereof
CN110621779B (zh) * 2017-05-12 2024-05-14 诺维信公司 具有溶菌酶活性的多肽、编码其的多核苷酸以及其用途和组合物
US11859170B2 (en) 2017-05-12 2024-01-02 Novozymes A/S Polypeptides having lysozyme activity, polynucleotides encoding same and uses and compositions thereof
CN110621779A (zh) * 2017-05-12 2019-12-27 诺维信公司 具有溶菌酶活性的多肽、编码其的多核苷酸以及其用途和组合物
EP3622075A4 (fr) * 2017-05-12 2021-05-19 Novozymes A/S Polypeptides ayant une activité lysozyme, polynucléotides codant pour ceux-ci et utilisations et compositions associées
CN111491518A (zh) * 2017-12-20 2020-08-04 帝斯曼知识产权资产管理有限公司 包含胞壁质酶的动物饲料组合物及其用途
CN111492053A (zh) * 2017-12-20 2020-08-04 帝斯曼知识产权资产管理有限公司 动物饲料组合物及其用途
WO2019121938A1 (fr) * 2017-12-20 2019-06-27 Dsm Ip Assets B.V. Compositions d'aliments pour animaux contenant de la muramidase et leurs utilisations
WO2019121930A1 (fr) * 2017-12-20 2019-06-27 Dsm Ip Assets B.V. Compositions d'aliments pour animaux et leurs utilisations
WO2019121937A1 (fr) * 2017-12-20 2019-06-27 Dsm Ip Assets B.V. Compositions d'aliments pour animaux comprenant de la muramidase et leurs utilisations
WO2019207053A1 (fr) * 2018-04-25 2019-10-31 Novozymes A/S Compositions d'aliments pour animaux et leurs utilisations
US12133542B2 (en) 2018-04-25 2024-11-05 Novozymes A/S Animal feed compositions and uses thereof
WO2020058223A1 (fr) * 2018-09-17 2020-03-26 Dsm Ip Assets B.V. Composition d'aliment pour animaux et son utilisation
WO2020058225A1 (fr) * 2018-09-17 2020-03-26 Dsm Ip Assets B.V. Compositions d'aliments pour animaux et leurs utilisations
JP2022500358A (ja) * 2018-09-17 2022-01-04 ディーエスエム アイピー アセッツ ビー.ブイ.Dsm Ip Assets B.V. 動物用飼料組成物及びその使用
JP7518814B2 (ja) 2018-09-17 2024-07-18 ディーエスエム アイピー アセッツ ビー．ブイ． 動物用飼料組成物及びその使用
EP4581938A3 (fr) * 2018-09-17 2025-08-20 DSM IP Assets B.V. Compositions d'aliments pour animaux et leurs utilisations
US12439939B2 (en) 2018-09-17 2025-10-14 Novonesis Animal Biosolutions Ag Animal feed compositions and uses thereof

Also Published As

Publication number Publication date
CA3001389A1 (fr) 2017-04-20
CN108289478A (zh) 2018-07-17
CL2018000925A1 (es) 2018-08-03
EP3361882A1 (fr) 2018-08-22

Similar Documents

Publication Publication Date Title
WO2017064092A1 (fr) Additifs alimentaires pour animaux aquatiques comprenant des huiles essentielles et un lysozyme
EP3316699B1 (fr) Compositions d'aliments pour animaux comprenant du lysozyme gh25 et de la 4-phytase et leurs utilisations
AU2016288515B2 (en) Methods of improving animal performance
CA2767873C (fr) Utilisation de substances naturelles en tant qu'additifs alimentaires pour animaux aquatiques
EP3784048A1 (fr) Compositions d'aliments pour animaux et leurs utilisations
EP3203858A1 (fr) Souches de bacillus à germination rapide et à activité antimicrobienne contre clostridium perfringens
WO2017147130A2 (fr) Produits microbiens administrés directement pour la prévention de la maladie des crevettes
CN111787810A (zh) 包含胞壁质酶的反刍动物饲料组合物
AU2019339736B2 (en) Animal feed composition and use thereof
BR112021004464A2 (pt) composição de ração animal e uso da mesma
CN112689461A (zh) 动物饲料组合物及其用途
BR112021004812A2 (pt) composições de ração animal e usos das mesmas
JP7484885B2 (ja) 動物用飼料組成物及びその使用
US20240122209A1 (en) Animal feed compositions and uses thereof
BR112021004817A2 (pt) composições de ração animal e usos das mesmas
WO2023131629A1 (fr) Composition d'aliment pour animaux et son utilisation
CN116981365A (zh) 动物饲料组合物及其用途
EA048229B1 (ru) Кормовая композиция, содержащая микробную мурамидазу, для снижения поражения животных пододерматитом

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16784817

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3001389

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2016784817

Country of ref document: EP